Whitepapers
Trends to look out for in 2023
By: Sophie Schmitz, Akshay Kumar, Joanna Fernandes, Chloe Sheppard, Srishti Gupta, Andrea Bernardini, Fisentzos Stylianou, Olivia Johns, Priyanka Kiritharan & Jodie Lyons Introduction In 2022
Trends to look out for in 2022
By: Sophie Schmitz, Akshay Kumar, Richard Wang, Fisentzos Stylianou, Adama Anozie, Chloe Sheppard, Nadia Al Lahiq, Andrea Bernardini & Sylwia Lach Introduction 2021 saw the
Hospital Exemptions: Friend or foe to Pharma?
By: Richard Wang, Adama Anozie Akshay Kumar & Bruce Chin What is Hospital Exemption? In recent years, we have seen rapid commercial development of advanced
Pan-European Joint HTA: What does the future hold for innovative therapies?
In January 2018, the European Commission released a legislative proposal on Health Technology Assessment (HTA) with the overarching goal to strengthen cooperation among national HTA
Innovative access agreements for ATMPs in Europe
Why embrace them? By Chloe Sheppard, Erfan Akbraian, Andrea Bernardini & Richard Wang Advanced Therapy Medicinal Products (ATMPs) have significant potential to transform the lives
BeNeLuxA and FiNoSe joint initiative
Are they as beneficial to manufacturers as they seem? By Joana Fernandes & Ashkay Kumar What are the research aims? Products that are being reviewed
Expanded Access Programs (EAPs) in Europe
Are they right for your therapy? By Maximus Rex & Nicola Allen Drug development is a long and costly process. It is not uncommon for
Tools for 2020 success: 10 trends you should know in orphan drug, cell and gene therapy
2019 set the tone for innovative therapies in the cell and gene therapy space along with huge interest from Big Biotech. With an expected double
Treatment without borders for Cell & Gene Therapies: Are we there yet?
“Cross border access”, “hub models”, “highly centralised access models” are only a few buzz words to refer to the pathway that enables European Union (EU)
